Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Iadademstat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oryzon Presents Iadademstat AML Data at 67th ASH Annual Meeting
    Oryzon Presents Iadademstat AML Data at 67th ASH Annual Meeting

    09 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202300/0/en/ORYZON-Presents-Data-for-Iadademstat-Combinations-in-AML-at-the-American-Society-of-Hematology-ASH-67th-Annual-Meeting.html

    GLOBENEWSWIRE
    09 Dec 2025
    Share Share
    ORYZON Reveals Positive Iadademstat Clinical Data At ASH-2025
    ORYZON Reveals Positive Iadademstat Clinical Data At ASH-2025

    04 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/04/3180259/0/en/ORYZON-Announces-Positive-Clinical-Data-of-Iadademstat-at-ASH-2025.html

    GLOBENEWSWIRE
    04 Nov 2025
    Share Share
    ORYZON Initiates First Patient In Iadademstat Phase Ib Trial
    ORYZON Initiates First Patient In Iadademstat Phase Ib Trial

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/03/3179181/0/en/ORYZON-Announces-First-Patient-In-FPI-in-RESTORE-Phase-Ib-Trial-of-Iadademstat-in-Sickle-Cell-Disease.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share
    Oryzon Bolsters Iadademstat Patent Portfolio With European Grant
    Oryzon Bolsters Iadademstat Patent Portfolio With European Grant

    01 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/01/3159429/0/en/ORYZON-Strengthens-Patent-Portfolio-for-iadademstat-with-European-Grant-Decision-Covering-Combinations-with-PD1-PD-L1-Inhibitors.html

    GLOBENEWSWIRE
    01 Oct 2025
    Share Share
    Oryzon Bolsters Patent Portfolio for Iadademstat and Vafidemstat
    Oryzon Bolsters Patent Portfolio for Iadademstat and Vafidemstat

    16 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/16/3150714/0/en/ORYZON-Strengthens-Patent-Portfolio-for-Iadademstat-and-Vafidemstat-with-New-Decisions-to-Grant.html

    GLOBENEWSWIRE
    16 Sep 2025
    Share Share
    ORYZON Doses First Patient in NCI Phase I/II Trial for Lung Cancer
    ORYZON Doses First Patient in NCI Phase I/II Trial for Lung Cancer

    15 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/15/3061672/0/en/ORYZON-Announces-First-Patient-Dosed-in-NCI-Sponsored-Phase-I-II-Clinical-Trial-of-Iadademstat-Plus-Immune-Checkpoint-Inhibitors-in-1L-Extensive-Stage-Small-Cell-Lung-Cancer.html

    GLOBENEWSWIRE
    15 Apr 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.